Immunic (IMUX) Competitors $0.95 +0.01 (+0.54%) Closing price 04:00 PM EasternExtended Trading$0.94 -0.01 (-0.53%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. YMAB, VIGL, ATXS, ABEO, FULC, ADCT, CAPR, ZYBT, TNXP, and CTMXShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Astria Therapeutics (ATXS), Abeona Therapeutics (ABEO), Fulcrum Therapeutics (FULC), ADC Therapeutics (ADCT), Capricor Therapeutics (CAPR), Zhengye Biotechnology (ZYBT), Tonix Pharmaceuticals (TNXP), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Y-mAbs Therapeutics Vigil Neuroscience Astria Therapeutics Abeona Therapeutics Fulcrum Therapeutics ADC Therapeutics Capricor Therapeutics Zhengye Biotechnology Tonix Pharmaceuticals CytomX Therapeutics Y-mAbs Therapeutics (NASDAQ:YMAB) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Do analysts rate YMAB or IMUX? Y-mAbs Therapeutics presently has a consensus price target of $9.62, indicating a potential upside of 12.80%. Immunic has a consensus price target of $7.50, indicating a potential upside of 689.47%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 2 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more risk and volatility, YMAB or IMUX? Y-mAbs Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Which has better earnings & valuation, YMAB or IMUX? Y-mAbs Therapeutics has higher revenue and earnings than Immunic. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$85.39M4.54-$29.67M-$0.50-17.06ImmunicN/AN/A-$100.51M-$1.23-0.77 Is YMAB or IMUX more profitable? Immunic has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-26.03% -24.60% -18.89% Immunic N/A -461.46%-217.16% Does the media refer more to YMAB or IMUX? In the previous week, Immunic had 1 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 2 mentions for Immunic and 1 mentions for Y-mAbs Therapeutics. Immunic's average media sentiment score of 0.12 beat Y-mAbs Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Y-mAbs Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in YMAB or IMUX? 70.8% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 19.7% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryImmunic beats Y-mAbs Therapeutics on 9 of the 16 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.72M$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.7721.1431.1525.96Price / SalesN/A398.37475.15122.97Price / CashN/A43.0937.1558.38Price / Book2.798.079.116.39Net Income-$100.51M-$54.72M$3.26B$265.56M7 Day Performance5.39%2.62%2.11%1.98%1 Month Performance1.48%7.63%5.12%1.33%1 Year Performance-37.50%13.11%31.25%21.15% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.5018 of 5 stars$0.95+0.5%$7.50+689.5%-42.0%$93.72MN/A-0.7770YMABY-mAbs Therapeutics2.1246 of 5 stars$8.53+0.1%$9.62+12.9%-38.4%$387.38M$87.68M-17.05150High Trading VolumeVIGLVigil Neuroscience1.9236 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340Positive NewsATXSAstria Therapeutics2.9519 of 5 stars$6.75-1.5%$29.00+329.9%-46.8%$381.53MN/A-3.3630ABEOAbeona Therapeutics4.4544 of 5 stars$7.01-1.8%$19.50+178.4%+35.7%$361.27M$3.50M10.0690News CoverageAnalyst RevisionFULCFulcrum Therapeutics0.9478 of 5 stars$6.66-2.4%$7.57+13.8%-31.7%$360.19M$80M-5.46100ADCTADC Therapeutics2.0554 of 5 stars$3.20+2.1%$7.75+142.5%+5.4%$359.66M$70.84M-2.04310CAPRCapricor Therapeutics3.1121 of 5 stars$7.77-2.4%$22.56+190.2%+53.1%$357.76M$22.27M-4.77101Trending NewsZYBTZhengye BiotechnologyN/A$7.50-0.1%N/AN/A$353.75M$186.36M0.00278News CoverageGap DownTNXPTonix Pharmaceuticals3.1734 of 5 stars$39.52-23.0%$70.00+77.1%-0.4%$353.15M$9.83M-1.0250High Trading VolumeCTMXCytomX Therapeutics4.0795 of 5 stars$2.13+11.3%$5.75+170.6%+59.8%$352.08M$138.10M3.81170 Related Companies and Tools Related Companies Y-mAbs Therapeutics Alternatives Vigil Neuroscience Alternatives Astria Therapeutics Alternatives Abeona Therapeutics Alternatives Fulcrum Therapeutics Alternatives ADC Therapeutics Alternatives Capricor Therapeutics Alternatives Zhengye Biotechnology Alternatives Tonix Pharmaceuticals Alternatives CytomX Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access